论文部分内容阅读
肝纤维化是各种肝细胞毒性物质对肝脏慢性或重复性的损伤所引起的肝脏病理改变,目前研究认为,肝星状细胞(HSC)激活是肝纤维化的核心。研究发现,脂联素可能通过抑制转化生长因子β1(TGF-β1)、血小板源性生长因子(PDGF)、肿瘤坏死因子-α(TNF-α)等的作用及减少α-平滑肌肌动蛋白(α-SMA)和细胞增殖细胞核抗原(PCNA)的表达等机制维持HSC静息状态、抑制HSC的活化及其增殖与迁移,并促进活化HSC凋亡,从而抑制肝纤维化发生发展,推测脂联素及其激动剂可能成为治疗肝纤维化的新药物。
Liver fibrosis is a variety of liver cytotoxic substances on the liver caused by chronic or repetitive damage caused by liver pathology, the current study suggests that hepatic stellate cells (HSC) activation is the core of liver fibrosis. It has been found that adiponectin may inhibit the effects of TGF-β1, PDGF, TNF-α, α-SMA and PCNA expression to maintain the resting state of HSC, inhibit the activation of HSC and its proliferation and migration, and promote the activation of HSC apoptosis, thus inhibiting the development of hepatic fibrosis. Supramolecular and its agonists may become new drugs for the treatment of liver fibrosis.